Mark Gooding supports clients on market access, product commercialization, and reimbursement policy.

With a focus on oncology and other physician-administered therapies, he applies his experience to provide customers with guidance on coding, coverage, and reimbursement issues.

Prior to joining Avalere, Mark was a senior associate at Covance Market Access Services, where he supported pharmaceutical manufacturers by conducting market research with payers and providers on issues, including coverage decision-making, reimbursement and financial support program development, and alternative payment models. He also provided support through bench-marking, policy analysis, and coding application strategy. Prior to that, as a project manager and research assistant at George Washington University’s Department of Health Policy, he provided support on an array of subject areas including healthcare reform, state Medicaid policy, and early childhood development.

Mark earned an MPS in political management from the George Washington University and a BA in political science and philosophy from Wake Forest University.

Authored Content

A shifting policy landscape and emerging market forces could introduce significant disruption in the kidney care space in the coming years. Understanding the risks and opportunities that these changes may present will be critical for patients, providers, payers, and manufacturers alike.

Tune in to hear the final episode in our 3-part series that focuses on CMS’s most recent proposed payment rules. In episode 3, we’ll be focusing on the End Stage Renal Disease (ESRD) Prospective Payment System, with a focus on proposed payment changes for innovative drugs, supplies, and equipment and updates to the Quality Incentive Program (QIP).

Manufacturers currently face an almost-unprecedented level of uncertainty in developing contracting strategies for the coming plan years. Avalere’s combination of policy and commercialization expertise, paired with its data capabilities, allow us to support life sciences companies understand this challenging landscape to ensure access to innovative therapies for their patients.

Additional Medicare payment options available for new, high-cost technologies used in the inpatient setting.

Recent developments in the specialty pharmaceutical marketplace merit distinct attention from manufacturers.

The interaction of recently announced drug pricing reforms will have differential implications for stakeholders.